Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
4.21M | 5.72M | 5.75M | 4.78M | 4.78M | 2.06M | Gross Profit |
-6.08M | -41.85M | -7.29M | -1.87M | -6.67M | -2.25M | EBIT |
-103.35M | -115.52M | -106.75M | -75.24M | -13.30M | -6.26M | EBITDA |
-83.27M | -95.46M | -91.36M | -99.77M | -12.59M | -5.83M | Net Income Common Stockholders |
-97.67M | -110.57M | -104.90M | -100.96M | -14.57M | -6.80M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
13.09M | 97.66M | 164.43M | 252.57M | 69.87M | 13.09M | Total Assets |
0.00 | 217.30M | 321.01M | 426.19M | 88.57M | 19.47M | Total Debt |
0.00 | 15.96M | 22.98M | 20.01M | 14.50M | 6.02M | Net Debt |
13.09M | -56.41M | -36.97M | -232.56M | -55.37M | -7.07M | Total Liabilities |
0.00 | 41.12M | 46.59M | 60.09M | 178.00M | 60.63M | Stockholders Equity |
11.60M | 176.18M | 274.41M | 366.11M | -89.43M | -41.16M |
Cash Flow | Free Cash Flow | ||||
-70.76M | -65.50M | -97.51M | -98.64M | -13.15M | -7.13M | Operating Cash Flow |
-70.36M | -64.64M | -81.34M | -60.60M | -10.97M | -6.03M | Investing Cash Flow |
-41.66M | 81.94M | -126.98M | -67.38M | -2.17M | -1.09M | Financing Cash Flow |
80.31M | -4.48M | 5.24M | 336.19M | 70.97M | 12.71M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $597.29M | 13.83 | 20.50% | ― | 2333.50% | ― | |
64 Neutral | $583.12M | ― | ― | ― | ― | ||
54 Neutral | $489.38M | ― | -204.78% | ― | 44.92% | -40.06% | |
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% | |
40 Underperform | $354.61M | ― | -48.98% | ― | -9.95% | 20.78% | |
40 Underperform | $195.70M | ― | 87.26% | ― | ― | -43.76% | |
33 Underperform | $523.29M | ― | -71.44% | ― | ― | 19.94% |
On May 13, 2025, Absci Corporation announced the initiation of its first-in-human study for ABS-101, marking its transition to a clinical-stage biotech company. The company also shared promising preclinical data for ABS-201, indicating potential for a more effective treatment for androgenetic alopecia. Financially, Absci reported a net loss of $26.3 million for Q1 2025, with cash reserves expected to fund operations into the first half of 2027. The company’s strategic focus remains on advancing its internal pipeline and expanding partnerships, with anticipated new collaborations in 2025.
The most recent analyst rating on (ABSI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.